Drug Trial Radar · NCT05502367
A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia
Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
44
Actual
Start
Sep 10, 2022
Primary completion
Oct 27, 2025
Study completion Oct 27, 2025
Sponsor
- Lead sponsor
- Antiva BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Aug 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 25 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B. Part A consists of up to 9 dose escalation cohorts. Part B consists of dose expansion cohorts. Participants will self-administer ABI-2280.
Conditions
- Cervical Intraepithelial Neoplasia
Interventions
ABI-2280 Vaginal Tablet/InsertDrug
Vaginal Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (Safety and Tolerability)Time frame: From Baseline to Day 42 post dose administration
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
East Sydney Doctors
Darlinghurst, New South Wales, Australia
CerviCusco
Cusco, Peru
Ginobs S.A.
Lima, Peru
Farmovs
Bloemfontein, Free State, South Africa
Nafasi Integrated Solutions
Sunnyside, Gauteng, South Africa
Botho ke Bontle Health Services
Waltloo, Gauteng, South Africa
Gole Biomedical Research Centre
Ga-Mothapo, Limpopo, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.